NCI Definition: A benign, borderline, or malignant tumor that originates from the surface epithelium of the ovary. It is composed of epithelial cells and stroma. Representative examples of benign tumors include serous cystadenoma, mucinous cystadenoma, and benign Brenner tumor. Representative examples of borderline tumors include serous surface papillary tumor, mucinous adenofibroma, and borderline Brenner tumor. Representative examples of malignant tumors include serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, and malignant Brenner tumor. [1]

Ovarian epithelial tumors most frequently harbor alterations in TP53, KRAS, PIK3CA, ARID1A, and CCNE1 [2].

Most Commonly Altered Genes in Ovarian Epithelial Tumor

TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, TP53 Exon 5 Mutation, and TP53 Exon 8 Mutation are the most common alterations in ovarian epithelial tumor [2].

Top Alterations in Ovarian Epithelial Tumor

Significant Genes in Ovarian Epithelial Tumor

CDK4 +

CDK6 +


Disease Details

Epithelial Tumor of Ovary, Epithelial Tumor of the Ovary, Epithelial Neoplasm of Ovary, Ovarian Surface-Epithelial Stromal Neoplasm, Ovarian Surface Epithelial-Stromal Tumor, Epithelial Neoplasm of the Ovary
Ovarian Neoplasm
Ovarian Squamous Cell Tumor, Ovarian Transitional Cell Tumor, Ovarian Papillary Tumor, Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor, Borderline Ovarian Epithelial Tumor, Malignant Ovarian Epithelial Tumor, Ovarian Mucinous Tumor, Ovarian Serous Tumor, and Ovarian Brenner Tumor
OncoTree Name
Ovarian Epithelial Tumor
OncoTree Code


1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.